Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes

European Journal of Cancer

Volumn 30, Issue 2, 1994, Pages 150-153

  de Graaf, H ^a   Willemse, P H B ^a   de Vries, E G E ^a   Sleijfer, D Th ^a   Mulder, P O M ^a   van der Graaf, W T A ^a   Smit Sibinga, C Th ^b   van der Ploeg, E ^a   Dolsma, W V ^a   Mulder, N H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; PREDNISONE; TAMOXIFEN; THIOTEPA; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEART FAILURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SEPTICEMIA; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMAN; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGE; PREDNISONE; PROGNOSIS; VINCRISTINE;

EID: 0028203445     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)90076-0     Document Type: Article

References (27)

1. Pathologic findings from the NSABP protocol no 4. VI. Discriminants for 5-year treatment failure
2. Cancer of the breast
3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
4. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer
5. Average relative dose intensity and the impact on design of clinical trials
6. Dose: a critical factor in cancer chemotherapy
7. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer
8. High dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors
9. Transfusion associated graft-versus-host disease in autologous bone marrow transplantation
10. High dose etoposide with or without cyclophosphamide and autologous bone marrow transplantation in solid tumors
11. High-dosage chemotherapy with autologous bone marrow reinfusion in the treatment of patients with solid tumours
12. Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy
13. Doxorubicin containing adjuvant therapy for patients with stage II breast cancer: MD Anderson Cancer Center Experience
14. Sixteen week dose intense chemotherapy in the adjuvant treatment of breast cancer
15. High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer
16. Growth-factor supported high-dose sequential adjuvant chemotherapy in breast cancer with 〉 10 nodes
17. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer
18. Dose intensive therapy in breast cancer: current status
19. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract
20. Incidence and effects of herpes simplex virus infection after autologous bone marrow transplantation for solid tumours
21. Effect of recombinant human GM-CSF in hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation
22. GM-CSF to harvest circulating haemopoietic stem cells for auto-transfusion
23. Outpatient bone marrow harvesting without general anesthesia
24. Bleeding prophylaxis in autologous bone marrow transplantation for solid tumors
25. Clinical application of cryopreserved stem cells and platelets in a bone marrow transplant program
26. Hyperalimentation in autologous bone marrow transplantation for solid tumors: comparison of total parenteral versus partial parenteral plus enteral nutrition
27. Progress in chemotherapy for metastatic breast cancer